Temozolomide in the chemo-immuno-therapy of refractory acute leukaemia of adult patients: The TRIAC protocol

Trial Profile

Temozolomide in the chemo-immuno-therapy of refractory acute leukaemia of adult patients: The TRIAC protocol

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2012

At a glance

  • Drugs Aldesleukin; Clofarabine; Cytarabine; Etoposide; Fludarabine; Hydroxycarbamide; Prednisone; Temozolomide; Tioguanine; Vinblastine; Vindesine; Vinorelbine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms TRIAC
  • Most Recent Events

    • 07 Jul 2012 Actual initiation date (26 May 2009) added as reported by European Clinical Trials Database.
    • 07 Jul 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 22 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top